The Prospecive OBSERVational Munich Interventional MITRAl-Valve Registry

Deutsches Herzzentrum Muenchen5,000 enrolled

Overview

Prospective, single-center observational registry including all consecutive patients treated with transcatheter mitral or tricuspid valve therapy at the Deutsches Herzzentrum München, Germany.

Long-term mortality after transcatheter mitral or tricuspid valve therapy

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Mitral Valve Regurgitation Mitral Valve Stenosis Tricuspid Valve Regurgitation

Interventions

edge-to-edge valve repairDEVICE

edge-to-edge valve repair

Eligibility

Sex: ALLMin age: 18 YearsMax age: 110 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age above 18 years and consentable * Mitral Valve Regurgitation, Mitral Valve Stenosis, Tricuspid Valve Regurgitation, Tricuspid Stenosis * Transcatheter mitral or tricuspid valve therapy considered best option by heart-team decision * Written informed consent Exclusion Criteria: * Patient's inability to fully cooperate with the protocol

Locations (1)

Deutsches Herzzentrum München des Freistaates Bayern, Technische Universität München

Munich, Bavaria, Germany

RECRUITING

Outcomes

Primary Outcomes

Long-term mortality

Time frame: 5 years

Central Contacts

Patrick Mayr, MD

CONTACT

+498912180 mayrp@dhm.mhn.de

Joner Michael, Prof

CONTACT

+498912180 joner@dhm.mhn.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.